Significant changes in the study of obesity and cardiometabolic disorders have occurred over the past few years in early-stage research.
Image Credit: Pixel-Shot/Shutterstock.com
Science is progressing, but the complexities of working with this patient population continue to challenge traditional trial design. The focus is no longer solely on speed. It is on precision, reproducibility, and clinical relevance.
Laboratories are no longer peripheral. They are essential to modern clinical development, enabling quicker decision-making, more accurate endpoints, and better alignment between mechanism and outcome. This position became increasingly apparent over the last year.
What was observed in 2025: Labs are accelerating early-phase development
Increasingly, sponsors are using parallel trial designs that combine aspects of Phases I and II to shorten study duration.
In metabolic disease, this includes early incorporation of patient cohorts, even in first-in-human studies where only healthy volunteers had previously been involved.
Regulatory authorities and ethics committees support this change, provided the necessary infrastructure and safety standards are in place.
Laboratories must be equipped to handle such complexity. Imaging methods for accurate evaluation of body composition and energy expenditure, along with validated metabolic laboratory tests such as adiponectin, leptin, ghrelin, visfatin, as well as inflammatory markers such as IL-6, TNF-alpha, and miRNAs, are gaining popularity.
Without them, it is difficult to meet the requirements of regulators and sponsors.
Obesity trials are becoming more precise
The primary endpoint is no longer simply weight loss. In 2025, the emphasis shifted to studying the type of weight loss (fat versus muscle) and fat distribution (ectopic versus subcutaneous), and how these factors affect obesity-related comorbidities.
This divergence has substantial clinical implications. Preserving lean mass is crucial, especially as new medicines begin to alter both energy expenditure and food consumption.
Answering these questions requires objective measurements. Imaging, metabolic profiling, and reliable lab methodologies are required to generate data for regulatory and clinical decisions.
A broader view of patient care
GLP-1 receptor agonists and incretin-based therapies have been demonstrated to be beneficial for weight loss, improving glucose metabolism, and providing cardiorenal protection. Despite all these new treatments, there is still a strong demand for new medications.
Not all patients react the same way; patients will gain weight after stopping medication, and body composition may undergo considerable rearrangement. Patients require systematic support, such as high-protein meals, resistance exercise, and behavioral supervision, to sustain their results and minimize muscle loss.
The researchers discovered that individuals receiving these medicines often began making healthier eating choices and altering their overall lifestyle habits. However, this impact is unstable without reinforcement.
As a result, formal patient advice and assistance is always incorporated into the protocol and treatment, rather than being considered optional.
Recruitment is more complex
Inclusion criteria are getting more stringent, especially in comorbid populations like those with cardiovascular disease or MASLD. This makes recruitment more challenging. The researchers addressed this by increasing the patient database and enhancing the referral network with local doctors and specialists.
The goal is not just to discover patients, but to find the right patients - those who best meet the study's requirements and can create useful data. This method requires laboratory-enabled screening and systematic data collection.
What to expect in 2026: Personalized trial design will advance
The researchers anticipate that further trials will be stratified by phenotype, comorbidity profile, or expected medication response. This is not genetic treatment. It is a realistic technique to match patients with medications based on their mode of action.
As new medicines are developed - some targeting liver illness, others focusing on muscle preservation or cardio-renal protection - this level of accuracy will become increasingly important.
This tendency will go beyond treating body weight and body mass index. More tailored trial designs will also be required in infectious diseases, immunology, and oncology.
Laboratories will play a critical role in allowing this change, not only by facilitating biomarker-driven stratification and endpoint selection, but also by providing the infrastructure needed to assess complex, multi-system responses consistently and precisely.
Endpoints will expand
Losing weight is not enough. Sponsors will need to show muscle preservation, metabolic improvement, and behavioral sustainability. This will necessitate new endpoints, tests, and extended follow-up times.
It is expected that additional trials will involve imaging, metabolic panels, and longitudinal data gathering. These strategies are already in use in obesity studies and will most likely be used in other treatment areas where body composition is important.
Multi-agonist therapies will increase complexity
GLP-1/GIP/glucagon combos are already being developed. These medicines affect several biological pathways, necessitating more complicated study designs. It is difficult to measure satiety, lipid metabolism, and liver function simultaneously. It requires collaboration between clinical and laboratory teams.
This complication is not confined to obesity. As combination medicines become increasingly popular, demand for integrated lab support will grow across many indications.
Patient support will be required
The researchers anticipate that future studies in the cardiometabolic field will incorporate structured patient support, such as nutritional coaching and behavioral guidance, into standard research methods.
This is not just an ethical consideration. It is required for efficacy, particularly in chronic illnesses where long-term outcomes rely on consistent behavior modification.
Placebo-controlled trials will be reconsidered
In long-term studies with effective medicines, placebo arms are getting more difficult to justify. It is expected that future trials will utilize active comparators, aided by statistical tools that allow for indirect comparisons to previous placebo results.
This modification will necessitate careful planning and reliable laboratory data. However, it is an important step toward more ethical and clinically useful research.
Looking ahead
Obesity is not one disease. It takes several forms, with varying comorbidities and treatment outcomes. The same is true for numerous chronic conditions. This complexity requires a novel approach to clinical research, one that is faster, more exact, and more personalized.
Laboratories will be critical to this evolution. They are not just used for sample processing. They are key collaborators in trial design, patient engagement, and scientific validation.
Acknowledgments
Produced from materials originally authored by Prof. Dr. Thomas Forst from hVIVO.
About hVIVO
hVIVO plc is a science‑led early‑phase drug development company purpose‑built to meet the growing complexity of modern clinical research. The Company operates an integrated early‑phase ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision‑ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials.
With industry‑leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‑growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‑built human challenge units in the world, complemented by additional early‑phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.
The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‑of‑concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.